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Epigenetic silencing of immune-related genes is a striking feature of the cancer genome
that occurs in the process of tumorigenesis. This phenomena impacts antigen processing
and antigen presentation by tumor cells and facilitates evasion of immunosurveillance.
Further modulation of the tumor microenvironment by altered expression of immuno-
suppressive cytokines impairs antigen-presenting cells and cytolytic T-cell function. The
potential reversal of immunosuppression by epigenetic modulation is therefore a promis-
ing and versatile therapeutic approach to reinstate endogenous immune recognition and
tumor lysis. Pre-clinical studies have identified multiple elements of the immune system
that can be modulated by epigenetic mechanisms and result in improved antigen presen-
tation, effector T-cell function, and breakdown of suppressor mechanisms. Recent clinical
studies are utilizing epigenetic therapies prior to, or in combination with, immune therapies
to improve clinical outcomes.
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INTRODUCTION
Immune evasion is a complex phenomenon that entails alterations
in cancer cells and the microenvironment to inhibit recogni-
tion of tumor cells by immune infiltrating cells. This process
includes altered expression and presentation of tumor-associated
antigens (TAAs) and secretion of cytokines that promote a reg-
ulatory/inhibitory milieu of antigen-presenting cells (APC) and
cytolytic T cells (CTL). This complex process is driven by a mul-
titude of factors including altered epigenetic marks in tumor cells
that control gene expression. A growing body of literature also sug-
gests that epigenetic alterations can alter immune cell phenotype
and function, for both regulatory and cytolytic function. These
epigenetic modifications include alterations in DNA methylation
and histone modifications, such as acetylation and methylation.
The accumulation of epigenetic alterations during tumorigenesis
contributes to profound changes in genome-wide transcriptional
regulation and genetic stability that promotes immune evasion.
The availability of state-of-the-art technologies to screen epige-
netic alterations across a variety of malignancies has advanced our
understanding of defects in tumor regulation, and new therapeu-
tic approaches have been devised and studied to reverse epigenetic
silencing. Since site-specific epigenomic patterns may associate
with disease progression, epigenetics has also come into focus
for biomarker research (1). These reciprocal fields identify poten-
tial therapeutic strategies with integrated biomarkers focused on
epigenetic mechanisms to improve antitumor immune responses
(Figure 1).
INTRODUCTION TO EPIGENETICS
METHYLATION AND HYPOMETHYLATING AGENTS
DNA methylation is one of the most studied epigenetic phenom-
enon and involves the enzymatic conversion of cytosine residues
to 5-methylcytosine. This reaction is catalyzed by the five known
mammalian DNA methyltransferases (DNMTs) DNMT1, 3A, 3A2,
3B, and 3L (2). The conversion is typically restricted to cytosine
residues of cytosine-guanine dinucleotides called CpG sites. CpG
islands contain a high density of CpG sites, which are mostly
unmethylated in normal tissues (3). However, most cancers are
characterized by localized aberrant DNA hypermethylation of
CpG islands within the promoters of various genes (4), including
tumor suppressors involved in cell cycle control, cell growth, apop-
tosis, cell adhesion, DNA repair, angiogenesis, and cell adhesion
(5). Furthermore, DNA hypermethylation inhibits gene expres-
sion, as evidenced by numerous studies correlating promoter
methylation with transcriptional repression during both normal
processes as well as tumorigenesis (6–8).
Hypomethylating agents can be used to counteract hyperme-
thylation and restore gene expression. Hypomethylating agents
can generally be grouped into (a) nucleosidic or (b) non-
nucleosidic DNA methylation inhibitors (Table 1).
Nucleosidic DNA methylation inhibitors are incorporated into
the genome during DNA replication. Thus, this class of agents acts
only in tumor cells actively undergoing cell division. Agents such
as Azacitidine (AZA) and 5-aza-2′-deoxycitidine (5AZA2) were
originally synthetized in the 1960s to use as cytotoxic drugs with
potential anti-leukemic activity (9, 28, 29). However, their effect
on DNA methylation was not identified until later in the process
of drug development. 5AZA2 incorporates into DNA in place of
cytidine during S-phase and covalently binds DNMTs during the
process of DNA replication to ultimately prevent DNA methyla-
tion. 5AZA2 has a dual, dose-dependent antineoplastic action. At
high doses, it covalently traps DNMT into DNA leading to cyto-
toxicity. At lower doses, it suppresses tumor growth primarily via
hypomethylation of promoter CpG islands of tumor-suppressor
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FIGURE 1 | Epigenetic modifying agents can enhance multiple aspects of
an antitumor immune response. EMAs may boost tumor antigen
expression, endogenous antigen processing, increase surface CTA display in
context of MHC molecules, and boost presentation to T cells by increasing
expression of co-stimulatory molecules. EMAs may also enhance both
cellular and cytokine-mediated effector T-cell mechanisms and tumor lysis.
EMAs may alter checkpoint inhibition targeting the PD1/PD-L1 and
CTLA-4/CD28 axis resulting in more efficient effector T-cell mechanisms.
specific loci (9, 30). AZA is similar to 5AZA2 but can also incorpo-
rate into RNA in the form of azacytidine-triphosphate and directly
inhibit protein synthesis.
The restoration of gene expression mediated by hypomethy-
lating agents can impact tumor growth in a wide variety of
mechanisms. In prostate cancer (PC), 5AZA2 targets multiple
genes including the tumor-suppressor miR-146a microRNA and
the androgen receptor (AR). 5AZA2-induced miR-146a induction
correlated with both delayed tumor growth and disease progres-
sion of castrate-resistant PC (CRPC) in an LNCap xenograft
model. The miR46a promoter methylation pattern was also sug-
gested as a biomarker for progression from androgen-dependent
to androgen-independent phases of PC (1). Hypermethylation of
the AR promoter was shown to associate with PC tumorigenicity
and the therapeutic potential of epigenetic agents in addition to
anti-androgen therapy has been suggested in several pre-clinical
studies both in vitro and in vivo. 5AZA2 reduced tumorigenicity
and cell proliferation of PC cell lines and PC stem/progenitor cells
via AR promoter demethylation and AR induction (31). 5AZA2
also restored the antiproliferative and pro-apoptotic effects of the
AR-antagonist bicalutamide (BCLT) in both in vitro and in vivo
xenograft models (32). A second-generation derivative, 5AZA2-
p-deoxyguanosine (SGI-110) was formulated to protect 5AZA2
from cytidine-deaminase inactivation and prolong half-life. SG-
110 efficiently retarded tumor growth in an EJ6 bladder cancer
xenograft model with less toxicity compared to 5AZA2 in vivo
(33). Zebularine is a cytidine analog displaying both cytidine-
deaminase and DNMT inhibitor properties (34). An in vitro study
treated breast cancer cell lines with zebularine, potentiating the
antitumor effects of other epigenetic drugs including 5AZA2 and
SAHA by inhibiting tumor proliferation and clonogenic potential.
Other pre-clinical studies in AML and solid tumors found growth
inhibition by zebularine via cell cycle arrest and apoptosis induc-
tion via various pathways including p53-dependent endoplasmic
reticulum (ER) stress (35, 36).
Non-nucleosidic DNA methylation inhibitors directly inhibit
DNMT activity without incorporating into nucleic acids. The
best-studied agents in this class include hydralazine, procaine,
and procainamide. Hydralazine has been studied alone or in
combination with valproate acid/magnesium valproate in refrac-
tory solid tumors, and it was shown to restore chemosensitivity
in gemcitabine-resistant CaLo cervical cancer cell lines via his-
tone methyltransferase inhibition (37, 38). Hydralazine treatment
resulted in significant dose- and time-dependent growth inhi-
bition, increased apoptosis, DNA damage, cell cycle arrest, and
decreased invasiveness of DU145 PC cells via blockage of the
EGF-receptor pathway (39).
Procaine and procainamide are both derivatives of 4-
aminobenzoic acid, ester- and amide-, respectively. Procainamide
is a competitive inhibitor of DNMT1 hemimethylase activity
(40). In an MDA-231 xenograft model, both procainamide and
hydralazine demonstrated potent tumor-suppressor reactivation
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Table 1 | Hypomethylating agents currently in development.
Drug Drug description Development stage Reference
CYTOSINEANALOGS (COVALENTLY BIND dNMTs)
Azacytidine Among the best-studied agents, but has several disadvantages including high toxicity
and a short half-life. Can also incorporate into RNA, reducing specificity
FDA approved (9)
Decitabine Decitabine has a longer half-life than azacytidine and only incorporates into DNA,
increasing specificity over azacytidine
FDA approved (10)
SGI-110 A dinucleotide of decitabine and deoxyguanosine that results in a high resistance to
cytidine-deaminase cleavage. This may increase exposure time to decitabine while
increasing metabolic stability
Phase II (11)
Zebularine Lacks the 4′-amino group but covalently traps DNMTs similarly to other analogs. This
drug has less toxicity and increased chemical stability when compared to azacytidine
or decitabine
Pre-clinical (12)
CP-4200 An azacytidine derivative with an elaidic acid bound to the molecule that permits
diffusion through the cell membrane independent of common nucleoside
transporters, thus increasing cellular uptake but possibly decreasing specificity
Pre-clinical (13)
ADENOSINEANALOGS (INCREASE COMPETITION FOR DNMT SAM-BINDING SITES)
Cladribine Inhibits SAH hydrolase, which increases SAH concentration, thus increasing
competition for the SAM-binding sites of DNMTs
FDA approved (14)
Fludarabine Similar to cladribine FDA approved (14)
Clofarabine A hybrid of fludarabine and cladribine FDA approved (15)
NON-NUCLEOSIDE INHIBITORS (BLOCK DNMT1ACTIVE SITE/CATALYTIC ACTIVITY)
Procainamide Reduces DNMT1’s binding affinity to SAM and methylated DNA. Binds DNA
sequences with high CpG density, blocking DNMT translocation
FDA approved (16)
Procaine Inhibits DNMT by masking enzyme target sequences FDA approved (17)
Hydralazine Exact mechanism is controversial. Is thought to bind and block the DNMT1 binding site Phase III (16)
Disulfiram Hypothesized to inhibit the catalytic cysteine of DNMT1 Phase III (18)
RG108 A small molecule inhibitor of DNMT1 that acts by binding its active site with no
detectable toxicity
Pre-clinical (19)
IM25 A procainamide derivative and small molecule inhibitor of DNMT1. It has been shown
to be as potent as but less toxic than azacytidine
Pre-clinical (20)
Nanaomycin A A small molecule inhibitor of DNMT1 that is selective for DNMT3B, which is known to
be critical for de novo methylation
Pre-clinical (21)
NATURAL COMPOUNDS
Genistein Decreases DNMT1, DNMT3A, and DNMT3B concentration in prostate cancer cells,
but the extent of altered DNA methylation is unclear
Phase III (22)
Equol Isolated from soy beans, equol has been shown to have some hypomethylating
effect; however, its role in cancer is controversial, and it may even increase the
viability of metastatic cancer cells
Phase III (23)
Curcumin Binds DNMT1 and blocks its catalytic function with potency similar to some synthetic,
non-nucleoside DNMT inhibitors
Phase III (24)
EGCG A component of green tea that is shown to have chemopreventive characteristics.
Functions as a DNMT inhibitor by depleting the amount of SAM available, leading to
decreased DNMT activity
Phase III (25)
Resveratrol Found in grapes, resveratrol may function by blocking acetylation of STAT3 and
preventing STAT3-mediated targeting of DNMT1 to promoter CpG islands
Phase II (26)
Parthenolide Binds the catalytic cysteine of DNMT1 with low potency Pre-clinical (27)
including demethylation and re-expression of the estrogen recep-
tor (41). Procaine suppressed growth of MCF-1 breast cancer
cells simultaneously with demethylation events (17). New DNMT
inhibitors developed by conjugation of procainamide to L-RG08
or phthalimide showing strong cytotoxicity against DU145 and
HCT116 cell lines (42).
Natural plant-derived compounds have been also identified
as non-nucleosidic DNA methylation inhibitors and have been
extensively studied for global DNA methylation and tumor
inhibitory effects. Curcumin was shown to reactivate expression of
the Neurog1 gene via promoter CpG site demethylation in LNCap
cells. The promoter methylation status of Neurog1 was proposed
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as a potential biomarker to detect early PC (43). Genistein inhib-
ited the AKT signaling pathway in PC cells via demethylation and
deacetylation of histone-H3-lysine 9 at the PTEN, CYLD, p53,
and FOXO3 tumor-suppressor gene promoters (44). Resveratrol
was also shown to demethylate several tumor-suppressor promot-
ers and restore estrogen sensitivity in triple-negative breast cancer
cells by increasing estrogen receptor expression via the inhibition
of STAT3 acetylation (26). A clinical trial has been initiated to ana-
lyze tissue gene expression patterns in PC patients after genistein
treatment (NCT01126879).
HISTONE ACETYLATION AND HISTONE DEACETYLASE INHIBITORS
Histone modifications can increase spatial separation of DNA
from protein in the nucleosome to permit transcription factor
binding to promoter regions, leading to enhanced global gene
expression. Chromatin acetylation is regulated by the balanced
action between histone acetyltransferases (HAT) and deacety-
lases (HDAC). Histone deacetylase inhibitors (HDIs) block the
catalytic domain of HDACs preventing chromatin condensation
and transcriptional repression. HDIs have been intensively studied
as potential anticancer compounds both alone and in combina-
tion with other therapies in a wide variety of solid tumors and
hematologic malignancies with strong pre-clinical evidence for
antitumor activity (Table 2). In addition to increasing gene expres-
sion of various tumor suppressors, HDIs have also been shown
to exert tumor-selective apoptosis induction and proliferation
arrest via multiple mechanisms including induction of p21 and
the TRAIL-pathway (45). One HDI, suberoylanilide hydroxamic
acid (SAHA), suppressed tumor growth, invasion, and migration
of highly aggressive ovarian carcinomas by modulating a variety
of phenotype-related molecules including members of the cas-
pase pathway, the cell cycle regulator Cyclin B1, tumor-suppressor
genes (p21, p53), and tissue remodeling MMP-9 enzyme, among
others (46). SAHA promoted autophagy both alone and in com-
bination with 5AZA2 (47, 48) and enhanced T-cell and NK
cell-mediated tumor cell targeting by re-sensitizing tumor cells
for the TRAIL/Apo2L death receptor pathway in various cancer
types (49–54). Panobinostat (or LBH589) displays robust growth
inhibition of a wide range of melanoma phenotypes via direct
cytotoxicity and cell cycle arrest and is known to induce cell death
independently from the apoptotic machinery or death receptor
pathways, likely via mitochondrial damage (55, 56). Entinostat has
been tested in combination with AZA and SG-110 in lung can-
cer models, and these combination therapies highlighted robust
gene expression changes in key pathways of antitumor mecha-
nisms including cell cycle, apoptosis, tissue remodeling, and DNA
damage (57, 58).
Romidepsin is a unique natural compound originally isolated
in the early 1990s from Gram-negative Chromobacterium vio-
laceum from a Japanese soil sample and was FDA approved in 2009
for the treatment of cutaneous T-cell lymphoma. Romidepsin was
originally described as an anti-Ras molecule and later identified as
an HDAC inhibitor. Romidepsin induces G1 phase cell cycle arrest
(103) primarily via p21 induction (103, 104).
Sirtuins are potent regulators of cell division that promote sur-
vival. SIRT inhibitors have been tested as potential candidates for
novel anticancer agents in pre-clinical studies. Sirtinol, a SIRT1/2
Table 2 | Histone deacetylase inhibitors.
Drug Target Development Reference
HYDROXAMATES
Vorinostat Class I and II HDACs FDA approved (59)
Panobinostat Class I, II, and IV HDACs Phase III (60)
Belinostat Class I and II HDACs Phase II (61)
Abexinostat Class I and II HDACs Phase II (62)
Givinostat Class I and II HDACs Phase II (63)
Resminostat Class I and II HDACs Phase II (64)
Quisinostat Class I and II HDACs Phase II (65)
Pracinostat Class I, II, and IV HDACs Phase II (66)
Dacinostat Class I and II HDACs Phase I (67)
Pyroxamide HDAC1 Phase I (68)
CHR-3996 Class I HDACs Phase I (69)
CBHA Class I and II HDACs Pre-clinical (70)
Trichostatin A Class I and II HDACs Pre-clinical (71)
Oxamflatin Class I and II HDACs Pre-clinical (72)
MC1568 Class IIa HDACs Pre-clinical (73)
Tubacin HDAC6 Pre-clinical (74)
PCI-30451 HDAC8 Pre-clinical (75)
BENZAMIDES
Entinostat Class I HDACs (excluding
HDAC8)
Phase III (76)
Tacedinaline HDAC1, HDAC2, and
HDAC3
Phase III (77)
Mocetinostat Class I HDACs Phase II (78)
Chidamide HDACs 1, 2, 3, and 10 Phase II (79)
BML-210 Class I and II HDACs Pre-clinical (80)
M344 Class I and II HDACs Pre-clinical (81)
ALIPHATIC ACIDS
Valproic acid Class I and IIa HDACs Phase III (82)
Butyrate Class I and IIa HDACs Phase II (83)
Sodium butyrate Class I and II HDACs Pre-clinical (84)
CYCLIC PEPTIDES
Romidepsin HDAC1 and HDAC2 FDA approved (85)
Trapoxin A Class I and IIa HDACs Pre-clinical (86)
Apicidin Class I HDACs Pre-clinical (87)
SIRT INHIBITORS
Nicotinamide SIRT1 Phase III (88)
Splitomicin SIRT1 Pre-clinical (89)
EX-527 SIRT1 Pre-clinical (90)
Dihydrocoumarin SIRT1 Pre-clinical (91)
Tenovin-D3 SIRT2 Pre-clinical (92)
AGK2 SIRT2 Pre-clinical (93)
AEM1 and AEM2 SIRT2 Pre-clinical (94)
Cambinol SIRT1 and SIRT2 Pre-clinical (95)
Sirtinol SIRT1 and SIRT2 Pre-clinical (96)
Salermide SIRT1 and SIRT2 Pre-clinical (97)
Tenovin-6 SIRT1 and SIRT2 Pre-clinical (98)
OTHER
TMP-269 Class IIa HDACs Pre-clinical (99)
Psammaplin A Class I HDACs Pre-clinical (100)
Nexturastat A HDAC6 Pre-clinical (101)
RGFP966 HDAC3 Pre-clinical (102)
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inhibitor, suppressed growth of MCF-7 breast cancer cells via var-
ious pathways including G1 cell cycle arrest and induction of
apoptotic machinery by PARP cleavage, cytochrome c release,
Bax up-regulation, and BCL-2 down-regulation. Furthermore,
sirtinol elevated autophagy-related markers and increased tumor-
suppressor p53 acetylation (105). Inhibition of p53 deacetylation
was also shown as a key pathway of tumor suppression and cyto-
toxicity exerted by two novel SIRT2-specific inhibitors, AEM1 and
AEM2 (94).
EPIGENETIC MODIFYING AGENTS IN CANCER THERAPY
Clinical utility of epigenetic modifying agents (EMAs) has been
demonstrated in a growing body of clinical research studies.
Current FDA-approved EMAs include DNMT inhibitors Vidaza
(AZA), Dacogen (5AZA2) for AML and MDS, and HDAC
inhibitors Istodax (romidepsin) and Zolinza (vorinostat) for treat-
ment of cutaneous T-cell lymphoma. AZA and 5AZA2 have pro-
vided a significant advancement in treatment of high-risk hemato-
logic malignancies; however, their clinical efficacy and therapeutic
value in solid tumors is limited. This is due to many factors includ-
ing both the relative molecular instability and significant toxicity of
these agents. These dose-limiting toxicities include myelosuppres-
sion, fatigue, and infection (106). Furthermore, the lack of clinical
benefit at the maximally tolerated doses (MTD) of these agents in
patients with solid tumors significantly hindered interest in further
clinical development. However, recent studies utilizing EMAs with
doses lower than the MTD have found significant antitumor effects
renewing interest in these agents. Further pre-clinical work has led
to the development of alternative formulations to decrease toxic-
ity and improve pharmacokinetics of these agents (107, 108). For
example, the pharmacokinetic profile of the second-generation
derivative, 5-aza-2′-deoxycitidine-p-deoxyguanosine (SGI-110) is
promising, and this agent is being tested in AML, CMML, and
MDS in a Phase I/II dose escalation study (NCT 01261312).
Epigenetic aberrations have been shown to associate with resis-
tance to chemotherapy. Several studies addressed the potential of
EMAs to reinstate chemosensitivity. When 5AZA2 was admin-
istered prior to standard chemotherapy for AML patients, the
overall complete remission was 83% (NCT00538876) (109). A
recently concluded Phase I/II study on metastatic, docetaxel-
resistant CRPC studied the effect of AZA in combination with
docetaxel and prednisone and found significant PSA response,
favorable clinical outcome, and demethylation of tumor-derived
DNA (110). The efficacy of hydralazine and magnesium valproate
treatment prior to re-challenge with chemotherapy was addressed
in a Phase II clinical trial with patients with refractory, chemore-
sistant solid tumors (NCT00404508). This study reported a reduc-
tion in global DNA methylation, histone deacetylase activity, and
80% of the patients showed clinical benefits with partial response
or stable disease (111). A Phase I study in chemoresistant metasta-
tic melanoma (NCT00925132) assessed the potential of sequential
epigenetic therapy including 5AZA2 and panobinostat combined
with temozolomide chemotherapy. This regimen was generally
well tolerated by the cohort with no patient reaching dose-limiting
toxicity (112) and has advanced to Phase II testing to further evalu-
ate if EMAs may modify chemosensitivity and apoptosis. A Phase II
clinical study of hydralazine and valproic acid in combination with
neoadjuvant cytotoxic chemotherapy in locally advanced Stage IIB
and IIIA breast carcinoma (NCT00395655) reported an overall
response of 81% with complete clinical response in 31% of the
patients (113), as well as increased efficacy of conventional cyto-
toxic agents. A significant decrease in global DNA methylation and
in HDAC enzymatic activity was also observed. This study is being
continued in a randomized ongoing Phase III study to analyze the
efficacy of epigenetic cancer therapy. A Phase II evaluation of effi-
cacy of AZA and/or lenalidomide in relapsed/refractory follicular
and marginal zone lymphoma (NCT 01121757) is also ongoing.
Other novel EMAs are in development, such as chromosome-
remodeling bromodomain inhibitors (114). These agents have
promising pre-clinical data with robust, targeted antitumor effects
in a broad range of malignancies. Further clinical development,
including evaluation of optimal dosing strategies and toxicity
evaluations, will be required to evaluate potential combinator-
ial strategies with other agents. However, great potential exists for
these novel agents to be deployed in a range of clinical contexts.
EPIGENETICS AND ANTITUMOR IMMUNE RESPONSES
During tumorigenesis, epigenetic alterations play a key role in the
suppression of immune recognition and immune surveillance to
promote immune evasion via alterations in both the tumor and
microenvironment. Immunosuppression is a striking feature of
the global methylation pattern of the cancer genome, and it is also
a common feature that extends across heterogenous cancer phe-
notypes. The potential for EMAs to reverse these phenomena is
an exciting therapeutic approach to reinstate immune recognition
and enhance endogenous tumor clearance. Multiple studies have
indicated the potential of epigenetic therapies prior to or in com-
bination with immune therapies, which can act through a variety
of mechanisms to enhance antitumor immune responses. These
include improving immune recognition via expression, process-
ing, and presentation of TAAs in tumor cells and efficient recogni-
tion, T-cell activation, and lysis of tumor targets by immune cells.
It is within this complexity of an effective antitumor immune
response that epigenetic therapies could play multiple roles.
NOVEL TUMOR-ASSOCIATED ANTIGENS
Tumor immune evasion is due, in part, to tolerance for self-
antigens and reduced expression of neoantigens. In 1943, Gross
published a study demonstrating that foreign antigens expressed
by tumor cells may induce immune-mediated rejection of syn-
geneic tumor grafts (115). The identification of these TAAs and
their potential to enhance immunogenicity has been well stud-
ied in the field of tumor immunology. These novel TAAs include
cancer testis antigens (CTAs) or germline antigens as potential can-
didates for novel vaccine therapies. CTAs are ideal targets as their
expression occurs during tumorigenesis with expression confined
to the tumor. The otherwise limited expression in normal tis-
sue beyond the blood-testis barrier suggests these TAAs may be
highly immunogenic. However, expression of CTAs in medullary
thymic epithelial cells was previously reported (116), and further
evidence supported the existence of some level of central tolerance
against these germline antigens (117). CTA expression has been
detected in a wide variety of hematologic and solid tumors types,
although expression levels often vary between disease models, and
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significant heterogeneity can be observed at different tumor loci
within the same host or even the same lesion (118, 119). Lung,
ovarian, head and neck, bladder, PC, melanoma, and multiple
myeloma have been shown to express a considerable amount of
CTAs, and clinical trials have been testing CTA-based therapies
with promising results in these groups. Genome-wide analysis has
described CTAs as a heterogenous group of antigens characterized
by three distinct expression profiles: testis-restricted, testis/brain-
restricted, and testis-selective (120). Almost half of the discovered
CTAs are linked to the X chromosome (CG-X),which are predomi-
nantly testis-restricted. Other CTAs located on various autosomes
are typically involved in later stages of germ-cell differentiation
with lower antigenic potential (121, 122).
Although their function is not completely understood, prior
studies have demonstrated that CTAs play a role in orchestrat-
ing cell differentiation processes during germline development.
CTAs interact with transcriptional factors driving various signal-
ing pathways involved in gametogenesis, maintenance of genomic
integrity, mRNA regulation, metabolic activity, meiosis, and sperm
motility. Interestingly, most of the known CTAs show redundancy
in germline development as shown in small-animal knock-out
models. While the role of CTAs in tumor pathogenesis is even
less characterized, data suggest that besides regulating transcrip-
tional activity, CTAs also promote tumor development by sup-
porting cell cycle processes and the mitotic machinery including
centrosome formation, mitotic spindle assembly, chromosomal
alignment, and nuclear envelope breakdown. Additionally, CTAs
promote tumor growth by suppressing apoptosis signaling cas-
cades, inducing aberrant gene expression patterns and impairing
response to cancer treatment drugs.
Cancer testis antigens have been proposed for use as biomark-
ers of disease progression in multiple disease models. Microar-
ray screening of both primary and CRPC revealed remarkable
differences in CTA expression. The MAGEA/CSAG family was
up-regulated in CRPC but not in primary cancer. Interestingly,
PAGEA4 was shown as a strong marker of primary tumors and
was silenced in CRPC (123). A study on tumor biopsies demon-
strated that SSX expression was an exclusive marker of metastatic
lesions and was not detected in primary tumor tissue (124). The
expression pattern of 30 CTA antigens was evaluated in glioblas-
toma samples compared to normal brain tissue. Glioblastoma lines
co-expressing three to four CTAs were found to be associated with
significantly better overall survival (125). A study in patients with
PC (126) detected CTA-specific IgG in sera including NY-ESO-1,
LAGE-1, NFX-2, and SSX-2. SSX-2 mRNA levels were also sig-
nificantly elevated in metastatic PC tissue compared to primary
tumors or to benign prostate tissue (126). SSX proteins were also
up-regulated in MCH class I-deficient germline cells and in var-
ious types of advanced cancers with poor prognosis. SSX-2 was
most frequently expressed across prostate cell lines, but SSX-1 and
SSX-5 were also inducible after 5AZA2 treatment. SSX expres-
sion detected by immunohistochemical tissue arrays in patient
tumor samples was restricted to metastatic lesions with no expres-
sion detected in primary prostate tumors. Cross-reactive immune
responses to a dominant HLA-A2 SSX epitope (p103-111) were
observed after immunization of A2/DR1 transgenic mice with SSX
vaccines (124).
This tumor-specific expression suggests CTAs may be ideal
antigens for tumor-targeting vaccines. In fact, the first CTA was
discovered by studying a patient with unusually favorable cytolytic
immune responses against melanoma. The CD8-restricted antigen
was identified as MAGE-A1 (127). The MAGE family was subse-
quently recognized as a potent target to enhance tumor-specific
CTL cell responses (128) and have been extensively studied as a
promising candidate for therapeutic approaches. In 1994, Weber
et al. found that 40–50% of tissue samples obtained from patients
with advanced melanoma were positive for MAGE-1 from both
early and metastatic stages while a wide range of normal tis-
sue samples including tumor-infiltrating lymphocytes, peripheral
blood from patients with metastatic melanoma, melanocytes, and
benign nevus showed no expression of MAGE-1. Re-induction of
MAGE-1 expression in non-expressing cell lines led to HLA-A1
restricted antigen presentation and epitope-specific lysis by CTL
(129). HLA-A2-restricted T-cell receptors cloned from SSX-2-
seropositive melanoma patients showed epitope-specific reactivity,
tumor cell recognition, and tetramer binding when engineered
into peripheral blood leukocytes (130). In a DNA vaccine study,
improved SSX-2 immunogenicity was reported by introducing
peptide ligand modifications to increase binding affinity to HLA-
A2 molecules. This enhanced both the magnitude and efficiency of
the Th1-type antitumor CD8 T-cell responses and also resulted in a
more diverse T-cell-derived cytokine profile (124). Such improved
overall efficiency and quality of the epitope-specific responses
makes this a promising strategy to enhance tumor-targeting CTA
vaccination strategies.
A key regulatory mechanism of CTA expression in both nor-
mal and tumor tissue is epigenetic modification (131). Epigenetic
silencing is also one of the key changes associated with tumori-
genesis (132), and hypermethylation in CTA promoter regions
has been observed in various cancer types (133–136). Knockdown
models of DNMT1 and DNMT3b demonstrated the role of these
enzymes in mediating CG-X antigen gene repression and promoter
methylation (135). A considerable body of literature on multiple
tumor types has demonstrated that EMAs have the potential to
increase immunogenicity via the re-expression of numerous CTAs
(126, 129, 135, 137–139). In 1994,Weber et al. reported that 5AZA2
treatment induced MAGE-1 antigen expression in non-expressing
cell lines, but not in normal blood cells or melanocytes, and led
to HLA-A1-restricted, epitope-specific lysis by CTL (129). Simi-
larly, inducibility of SSX-2 gene in PC LNCap and DU145 cell lines
was found following 5AZA2 treatment but not in normal prostate
epithelium cell line RWPE1 (126). A subsequent study of the
same CTA family demonstrated that While SSX-2 was expressed
most frequently in PC cell lines, SSX1 and SSX5 expression was
also induced after 5AZA2 treatment (124). In a global screening
study of human epithelial cell lines, low-dose AZA treatment up-
regulated a wide selection of CTAs, including several members of
the MAGE, SSX, SPANX, PAGE families, which were induced in all
three tumor types analyzed (breast, colorectal, and ovarian) (140).
The inhibition of histone lysine methylation enhanced expression
of NY-ESO1, MAGE-A1, and MAGE-A3 expression in H841 lung
cancer cells and enhanced tumor cell targeting and lysis by MAGE-
A3 and NY-ESO1 epitope-specific T cells (136). HDIs Trichostatin
A and depsipeptide FR901228 were both shown to synergize with
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5AZA2 to activate CG-X antigen expression in various thoracic
and colorectal cancer cell lines (135, 141, 142).
Increased expression of CTAs following treatment with EMAs
has been identified in several clinical trials. In a Phase II study
for patients with multiple myeloma, sequential AZA and a
cytotoxicity-enhancer led to a significant increase of MAGEA4,
MAGEA6, SPA17, and AKAP4 in bone marrow compared to pre-
therapy samples. The treatment also resulted in enhanced CTAGB1
epitope-specific IFNγ response by patient PBMCs tested ex vivo
in response to monocyte-derived, CTAGB1-pulsed dendritic cells
(DCs) (143). NCT01483274 was proposed to test 5AZA2 effi-
ciency in up-regulating CTA expression followed by a donor
lymphocyte infusion and an autologous transfer of MAGE-A1,
MAGE-A3, and NY-ESO1 peptide-pulsed DCs in patients with
AML who had relapsed after an allogeneic stem cell transplant.
Study outcomes are specified as tolerance of study treatment,
clinical disease response, and assessment of immune responses
to vaccine peptides. The same center proposed a Phase I study
with the same treatment to treat relapsed high-risk neuroblas-
toma, Ewing’s sarcoma, osteogenic sarcoma, rhabdomyosarcoma,
or synovial sarcoma. Both of these studies are registered but not
yet recruiting.
CTAs have been identified as promising candidates for highly
selective tumor-targeting by enhancement of endogenous antitu-
mor responses. Conversely, a vaccine clinical trial with antigenic
targets from the same MAGE family, namely MAGE-A3/A9/A12
was just recently terminated due to adverse side effects including
substantial neurotoxicity with two vaccination induced fatalities
with necrotizing white matter tissue damage and CD8+CD3+ T-
cell neuro-infiltration. Follow-up studies revealed a previously
unrecognized expression of MAGE A12 in normal brain tissue,
which could be the potential target for the vaccine-mediated
neuroinflammatory response detected in this trial. This case has
alerted for the need of refining CTA characterization to help iden-
tify suitable and safe targets for systemic immunization against
cancer (144).
ANTIGEN PROCESSING AND ANTIGEN PRESENTATION
Beyond sufficient expression of TAAs, effector antitumor T-cell
responses also require the processing and loading of TAAs onto
major histocompatibility complex (MHC) I complexes in the con-
text of co-stimulatory molecules. The MHC I antigen-presenting
machinery samples designated ubiquitin-tagged endogenous pro-
teins and delivers them to the proteasome complex low molecular
mass polypeptide (LMP) 2, LMP7, LMP10 for preprocessing into
up to 25-meric peptides. This peptide-pool is then further cleaved
by cytosolic aminopeptidases and delivered to the ER via the trans-
porter associated with antigen processing (TAP) complex (TAP1,
TAP2) for subsequential trimming by ER aminopeptidase asso-
ciated with antigen processing (ERAAP) followed by chaperone
(calnexin, calreticulin, ERp57, and tapasin)-mediated assembly
and loading onto the antigen-MHC complex. After peptide load-
ing, the chaperones are released from the peptide-MHC complex,
which is then trafficked to the Golgi via vesicle transport and deliv-
ered for surface membrane display (145). Defects of the MHC I
antigen presentation system lead to impairment of immune sur-
veillance, which has been linked to both tumorigenesis and poor
clinical outcomes (146–150). A tissue microarray analysis on 71 PC
patient samples revealed a significant decrease in beta 2 microglob-
ulin (B2M) expression compared to normal surrounding tissue
(145). A study on diffuse large B cell lymphoma revealed aber-
rant B2M protein expression in 75% of the examined biopsies,
which was associated with the loss of HLA-I surface expression
(151–153).
Epigenetic alterations have been identified as one of the mech-
anisms underlying deficient antigen presentation in pre-clinical
tumor models. Histone acetylation of the TAP1 promoter was pro-
posed as a potential repressor mechanism accounting for TAP1
deficiency in various carcinoma cell lines. The level of acetyl-
histone H3 strongly correlated with the level of TAP1 expression
and with metastatic features in malignant carcinomas (154). The
reversal of tumor antigen presentation impairment and MHC-
complex deficiencies may promote tumor killing. EMA has been
shown as a potential approach to reverse such defect and enhance
tumor immune responses. Li et al. analyzed the global response
to low-dose AZA in 63 human epithelial cancer cell lines and
found that B2M, HLA-B, HLA-C, CTSS, NSF2, TAP1, and protea-
some proteins PMSB8 and PMSB9 were up-regulated in at least
three cell lines each (140). Using a high-throughput bioinformat-
ics approach, Kortenhorst et al. identified a comprehensive list of
genes and pathways affected by HDI treatment in PC cell lines
and showed a significant up-regulation of MHC genes including
HLA-Class I molecules and B2M (145). Antigen processing and
presentation is also enhanced by AZA treatment via up-regulation
of the interferon type I and type II families including interferon-
gamma receptor 1 and STAT1 as was shown in an in vivo mouse
model for HPV-16-associated tumors and in NSCLC tumor cell
lines (153, 155).
Dendritic cells play a pivotal role in TAA sampling, processing,
and presentation to T cells. Selective DC targeting makes antigen
delivery to the draining lymph nodes more efficient. Fusion pro-
teins with high-affinity DC-specific binding components facilitate
DC loading and shield antigens from biodegradation allowing for
lower vaccine doses. DC targeting has been shown to be a promis-
ing novel vaccination strategy that results in enhanced, durable,
and overall higher quality immune responses (156). A phase I trial
study has been registered (NCT01834248) and is currently recruit-
ing to test immune response to DEC-205/NY-ESO1 fusion protein
(CDX-1401) and 5AZA2 in patients with MDS or AML. CDX-1401
is a full length NY-ESO1 protein sequence fused to a monoclonal
antibody against DEC-205, a surface marker present on profes-
sional APCs to enhance targeted delivery of peptide antigen to
the antigen processing machinery and to enhance the efficacy of
DC-mediated T-cell induction. NY-ESO1-specific primed T cells
are expected to target tumor more efficiently due to an increase in
5AZA2-induced in situ NY-ESO1 expression by the cancer cells.
In addition to addressing safety, efficacy, tolerability, and vaccine
immune responses, the study also aims to assess the molecular
epigenetic response to 5AZA2.
EPIGENETICS AND ADAPTIVE IMMUNE RESPONSES
Epigenetic silencing of immune-related genes is a striking fea-
ture of the global methylation pattern of the cancer genome.
The impact of epigenetic alterations in tumorigenesis can foster
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an immunosuppressive tumor microenvironment. These alter-
ations are potentially modifiable with EMAs. A large-scale study
on epithelial cancer cell lines treated with low-dose AZA have
identified 80 up-regulated gene sets similar across three cancer
types analyzed including ovarian, colorectal, and breast cancer
and among those there were 15 commonly up-regulated immune
gene sets including elements of the interferon signaling, antigen
presentation, influenza, and the chemokine and cytokine fami-
lies. A similar analysis of lung cancer cell lines then also showed
a 95% overlap of the gene sets up-regulated by AZA as well as
a relative dominance among those by immune-related pathways.
The same study also analyzed primary tumor data in public gene
expression data bases and found that the above identified AZA-
responder immunomodulatory genes showed clustering into a
“low” and “high” expression subgroup across all three epithelial
cancer types independent of clinical stage or of most tumor sub-
types. Similar findings were concluded when looking at NSCLC
and melanoma databases. Strikingly, 11 of the 15 AZA-responder
immunomodulatory gene clusters were up-regulated in patient
biopsies following an 8-week AZA and entinostat combination
therapy. These findings suggest that gene expression profiling
may help identify patients with immune evasion phenotype as
candidates potentially benefiting from epigenetic therapy (140).
Effective T-cell priming requires the antigen presented in
the MHC complex in the context of co-stimulatory molecules,
which define the phenotype of T-cell responses. Modifying co-
stimulatory patterns in the immune synapsis can effectively alter
the magnitude of both effector and regulatory T-cell responses
(157). Therapeutic targeting of negative or positive co-stimulatory
molecules to enhance antitumor immune responses has been
tested in both pre-clinical and clinical studies with promis-
ing outcomes. Low-dose in vitro 5AZA2 treatment of EL4 cells
increased co-stimulatory CD80 expression by the tumor cells,
which led to increased immunogenicity detected after engraftment
into C57BL/6 mice (158). The addition of AZA and entinostat
to treatment with checkpoint-inhibitor anti-PD-1/anti-CTLA-4
antibodies led to remarkable tumor regression in a syngeneic
mouse model with checkpoint-inhibitor-resistant metastatic can-
cer (159). A study in human leukemia cell lines demonstrated that
AZA treatment increased the expression of immune-checkpoint
molecules PD-1, PD-L1, PD-L2, and CTLA-4 (160). AZA increased
both transcript and surface expression levels of PD-L1 on a NSCLC
cell line (153).
Targeting regulatory immune responses to enhance antitumor
immune responses has been addressed in several recent clinical
trials. Clinical response and prolonged stabilization were reported
in a substantial proportion of patients with diverse tumor types
even with treatment-refractory, metastatic types otherwise consid-
ered as non-responsive to immunotherapy. Notably, patients with
PD-L1 negative tumors showed no response to therapy (161). A
follow-up study of three patients for more than 3 years after cessa-
tion of anti-PD-1 therapy showed durable, stabile, or re-inducible
complete remission (162). Patients showing no up-regulation of
checkpoint elements after treatment with combination therapy of
AZA and vorinostat had increased survival (160). The analysis of
PD-L1 and PD-1 expression patterns within the tumor microenvi-
ronment revealed a strong correlation between tumor cell PD-L1
expression and both the magnitude of intratumoral immune cell
infiltration and their PD-1 expression. These findings suggested a
strong correlation between tumor PD-L1 expression and clinical
response (163). Since EMA treatment has a potential to restore PD-
L1 expression on tumor cells, combinatorial EMA treatment may
expand the group of candidates for PD-L1 checkpoint-inhibitor
therapy. A Phase II study in NSCLC (NCT01928576) is currently
recruiting to analyze the efficacy of entinostat and/or azacitidine
prior to PD-1 blocker nivolumab treatment.
Enhancement of effector immune mechanisms can benefit
antitumor interventions and therapeutic approaches to improve
clinical outcomes. Combining EMAs provides a novel alterna-
tive to improve antitumor immune responses. Importantly, data
from immunodeficient animal models have demonstrated that the
tumor inhibitory effect of EMAs requires an intact immune sys-
tem. The antitumor effect of HDI vorinostat and panobinostat
treatment was diminished in RAG2γC-/- and IFNγR-/- immuno-
compromised animals (164, 165). Pre-clinical studies have demon-
strated that hypomethylating agents enhance the effector function
of both T cells and NK cells. 5AZA2-treated tumor cells induced
a higher yield of tumor-infiltrating CD4, CD8 T cells, and NK
cells and IFNγ production was also elevated in both T-cell com-
partments. Mechanistic experiments within the same study iden-
tified a CD8-dependent tumor rejection mechanism induced by
5AZA2 (158). 5AZA2 treatment had a biphasic effect on both
the phenotype and function of ex vivo expanded normal human
peripheral NK cells. After treatment, KIR and NKp44 expres-
sion were increased while NKG2D decreased. The 5AZA2-induced
hypomethylation followed a U-shaped dose-response curve simi-
lar to the effects on cytotoxicity (166). Human peripheral NK cells
showed increased cytotoxicity when exposed to exosomes isolated
from MS-275-treated HEPG2 cells compared to untreated cancer
cells. The TAA chaperone HSP70 and the MHC-related MICA,
MICB content of the exosomes was elevated by MS-275 treatment
suggesting a non-antigen-specific mechanism selective for NK cell
activation (167). Combinatorial panobinostat treatment signifi-
cantly reduced tumor burden and enhanced TH1 cytokine profile
and effector function of adoptively transferred tumor-specific T
cells in a melanoma model. This treatment also resulted in a dra-
matic increase in the tumor-infiltrating effector cell to regulatory
T-cell ratio (168).
Previous studies have suggested that EMAs can impact T-
cell proliferation, differentiation, and function (169–171). Animal
studies support the concept that HDIs can promote a cytotoxic
antitumor immune response (172) but numerous studies have
shown that patients with PRCA have a profound impairment in the
function of circulating and tumor-infiltrating T cells (173, 174).
Whether EMAs can promote antitumor responses in this immuno-
suppressive environment in patients with PRCA is unknown.
Another challenge to this hypothesis lies in the clinical findings
of myelosuppression due to EMA treatment when given at high
doses or intervals (175–177). However, low doses of EMAs may
promote T-cell-mediated cell lysis (169).
As with any systemic therapy, there are potential toxicities
from EMAs that could inhibit antitumor immune responses
or complicate patient outcomes. For example, dose-dependent
toxicities with EMAs include leukopenia, granulocytopenia, and
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thrombocytopenia. Altering dose and schedule of these agents can
ameliorate some of these toxicities but must be closely monitored.
In addition, reactivation of chronic viral infections, including
HIV type 1, was reported following treatment with SAHA in
an in vitro model for latent infection (178). Virus-related ill-
nesses were also observed in a multi-institutional phase II clinical
trial of romidepsin, including EBV, HBV, and VZV reactivation
(179). Finally, epigenetic modification has been also suggested
to regulate immune mechanisms involved in chronic inflamma-
tion and autoimmunity. The extent to which these toxicities may
impact patient outcomes is unclear and is the subject of ongoing
clinical studies.
BIOMARKERS FOR EPIGENETIC THERAPIES
Studies have identified a wide variety of impacts that EMAs can
have on both the tumor and immune compartments. However,
the toxicities associated with these agents when dosed at tradi-
tional MTDs will likely mitigate effective immune responses. Thus,
optimal biologic dosing strategies may be key to the success of
these therapeutic strategies. Integration of biomarkers for the pur-
pose of assessing methylation and histone modification status in
tumor and immune compartments as well as expression of rele-
vant immune-related genes, could identify patient-specific dosing
strategies targeting immune activation. State-of-the-art tools are
available to dissect and measure immune responses quickly and
efficiently using multi-parameter analysis platforms and high-
throughput technologies. Improving tumor analytics for these
purposes, whether through traditional tumor biopsies or alternate
assays for tumor cells in circulation, may further identify opti-
mal biologic dosing strategies to modify gene expression. Given
the potential of these agents to alter expression of a wide range
of genetic targets, incorporation of discovery biomarkers to iden-
tify novel targets would have further clinical and experimental
utility. For example, large clusters of genes involved in effector
immune mechanisms have been identified as loci accumulating
genetic aberrations in the cancer genome. Only a limited num-
ber of individual genes from these clusters have been tested so far
in either pre-clinical or clinical studies in cancer research. Thus,
careful integration of biomarkers into these therapeutic strategies
will be critical to advance these clinical hypotheses.
CONCLUSION
In recent years, the development of combination immunothera-
pies has branched out as a robust new approach to novel cancer
therapeutics. The interplay between tumor and host during tumor
pathogenesis is a complex process and epigenetic modifications
mark many components of the pathologic changes leading to
tumor evasion. Epigenetic therapies have the potential to reverse
this process at multiple levels. Immune therapies provide a signifi-
cant benefit compared to standard cancer therapies by allowing for
better accommodation of tumor heterogeneity and the patient’s
individual immune repertoire. Epigenetic agents can complement
immunotherapies by enhancing many underlying mechanisms of
the antitumor immune response (Figure 1). However, the poten-
tial benefits of these agents must be balanced by the potential
toxicities of these therapies. Biologic dosing strategies are likely
the best approach to maximize benefit while limiting toxicity.
Integrated biomarkers across tumor and immune compartments
may allow determination of biologic doses, though thoughtful
approaches to these assays must be considered.
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